Next 10 |
In its recent 13-F filing , Larry Robbins and Mark Horowitz owned fund Glenview Capital indicated that it has acquired new stakes in Microsoft ( MSFT ) with 0.2M shares, Willis Towers Watson ( WTW ) with 0.13M shares, ZoomInfo Technologies ( ZI ) with 0.3M shares...
Myriad Genetics, Inc. (MYGN) Q2 2022 Earnings Conference Call August 04, 2022, 16:30 ET Company Participants Foster Harris - IR Paul Diaz - CEO, President & Director Nicole Lambert - COO Bryan Riggsbee - EVP, CFO & Treasurer Conference Call Part...
The following slide deck was published by Myriad Genetics, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Myriad Genetics, Inc. 2022 Q2 - Results - Earnings Call Presentation
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due t...
Myriad Genetics press release ( NASDAQ: MYGN ): Q2 GAAP EPS of $0.04 beats by $0.19 . Revenue of $179.3M (+6.5% Y/Y) beats by $9.25M . GAAP gross margin in the second quarter of 2022 was 72.3%; adjusted gross margin in the quarter was 72.4%, which improved 30 b...
Highlights: Revenue of $179.3 million for the quarter ended June 30, 2022 Excluding revenue from divested businesses, revenue increased 7% year-over-year and 9% sequentially from the first quarter of 2022 D iluted GAAP earnings per share ...
Myriad Genetics ( NASDAQ: MYGN ) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is $0.02 (-83.3% Y/Y) and the consensus Revenue Estimate is $170.05M (-10.2% Y/Y). Over the last 2 years, MYGN has be...
SALT LAKE CITY, July 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its second-quarter earnings conference call on Thursday, Aug. 4, 2022 at 4:30 p.m. EDT. The company’s quarterly earnings will be...
SALT LAKE CITY, July 19, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will host an Investor Day on Aug. 11, 2022, providing a strategic business update and overview of the company’s growth opportunities, rese...
Shares of cancer diagnostics concern Veracyte, Inc. have shot up approximately 60% over the past month, snapping a deep decline. That said, valuations were stratospheric (22.6x FY21 sales at their peak), but shares of unprofitable Veracyte now trade at just under seven times FY22E sal...
News, Short Squeeze, Breakout and More Instantly...
Highlights: Revenue of $179.3 million for the quarter ended June 30, 2022 Excluding revenue from divested businesses, revenue increased 7% year-over-year and 9% sequentially from the first quarter of 2022 D iluted GAAP earnings per share ...
SALT LAKE CITY, July 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its second-quarter earnings conference call on Thursday, Aug. 4, 2022 at 4:30 p.m. EDT. The company’s quarterly earnings will be...
SALT LAKE CITY, July 19, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will host an Investor Day on Aug. 11, 2022, providing a strategic business update and overview of the company’s growth opportunities, rese...